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Purpose: To evaluate systemic risk factors of dry eye disease, aqueous tear deficiency, and 3 
meibomian gland dysfunction. 4 
 5 
Methods: Three hundred and seventy-two community residents (222 females, 150 males; 6 
mean±SD age, 39±22 years) were recruited in a cross-sectional study. Past medical history, 7 
dry eye symptomology, ocular surface characteristics, and tear film quality were evaluated 8 
for each participant within a single clinical session. The diagnosis of dry eye disease, 9 
aqueous tear deficiency, and meibomian gland dysfunction were based on the global 10 
consensus recommendations of the Tear Film and Ocular Surface Society Dry Eye 11 
Workshop II (TFOS DEWS II) and the International Workshop on Meibomian Gland 12 
Dysfunction. 13 
 14 
Results: Overall, 109 (29%) participants fulfilled the TFOS DEWS II criteria for dry eye 15 
disease, 42 (11%) had aqueous tear deficiency, and 95 (26%) had meibomian gland 16 
dysfunction. Multivariate logistic regression analysis demonstrated that systemic 17 
rheumatologic disease and antidepressant medication were independently associated with 18 
aqueous tear deficiency (both p<0.05). Significant risk factors for meibomian gland 19 
dysfunction included age, East Asian ethnicity, migraine headaches, thyroid disease, and 20 
oral contraceptive therapy (all p≤0.01). 21 
 22 
Conclusions: Both etiological subtypes of dry eye disease were associated with a number 23 
of systemic risk factors. These findings would support routine systemic inquiry of dry eye 24 
disease and associated systemic conditions and medications, in order to facilitate 25 
opportunistic screening and timely inter-disciplinary referral where necessary. 26 
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1. INTRODUCTION 32 
 33 
Dry eye disease is among the most frequently encountered chronic ophthalmic conditions in 34 
clinical practice, and affects between 5% to 50% of the population in different parts of the 35 
world.[1] The condition is acknowledged to have profound impacts on ocular comfort, visual 36 
function, quality of life, and work productivity, and is associated with significant financial and 37 
public health burden worldwide.[1-4] 38 
 39 
Dry eye disease is commonly divided into two etiological subtypes, described as aqueous 40 
deficient and evaporative disease, which represent inadequate production or excessive 41 
evaporative losses from the tear film.[2, 5] Evaporative dry eye disease is recognised to 42 
have a higher population prevalence than aqueous tear deficiency, and is commonly 43 
triggered by underlying meibomian gland dysfunction.[2, 6] However, regardless of the 44 
etiological mechanism, a self-perpetuating vicious cycle of tear film instability, hyper-45 
evaporation, hyperosmolarity, and ocular surface inflammation ensues, resulting in the 46 
development and progression of dry eye symptoms.[5]  47 
 48 
The recent Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) 49 
Epidemiology Report identified a number of probable and inconclusive risk factors for dry 50 
eye disease, and also highlighted the need for further research examining the associations 51 
of the condition with systemic disease and medications.[1] Considerable heterogeneities in 52 
methodologic design and disease definition were also noted to have introduced challenges 53 
when interpreting and comparing the findings of earlier epidemiology studies.[1] The 54 
purpose of this cross-sectional study was therefore to evaluate the systemic risk factors of 55 
two prominent drivers of dry eye disease – aqueous tear deficiency, and meibomian gland 56 
dysfunction – using diagnostic criteria and methodology that align with the global consensus 57 
recommendations of the TFOS DEWS II Diagnostic Methodology Report.[7] 58 
  59 
 
 
2. MATERIALS AND METHODS 60 
 61 
2.1. Subjects 62 
 63 
This cross-sectional study adhered to the tenets of the Declaration of Helsinki, and was 64 
approved by the University of Auckland Human Participants Ethics Committee. Participants 65 
were recruited through open advertisement at a single university centre between January 66 
2018 and June 2019, as part of a larger multi-arm epidemiology study of which the current 67 
cross-sectional study formed part. To minimise environmental differences, participants were 68 
required to be local community residents who had lived in the Auckland region for at least 15 69 
years. Furthermore, eligibility required participants to be 16 years or older, with no contact 70 
lens wear 48 hours prior to study participation, and no ophthalmic surgery in the previous 71 
three months. Eligible participants were enrolled after providing written consent. The sample 72 
size was pragmatically determined by the number of participants enrolled during the 73 
recruitment period. 74 
 75 
2.2. Measurements 76 
 77 
Participants were assessed at a single site, within a temperature and humidity-controlled 78 
environment, with a mean±SD room temperature of 20.1±0.5°C and a mean±SD relative 79 
humidity of 63.5±6.2%, and ocular measurements were conducted on the right eye of each 80 
participant. Clinical measurements were conducted in accordance with the 81 
recommendations of the TFOS DEWS II Diagnostic Methodology subcommittee.[7] To 82 
minimise the impact on ocular surface and tear film physiology for subsequent assessments, 83 
clinical measurements were performed in ascending order of invasiveness,[7] as listed in 84 
Table 1. The diagnostic criteria for dry eye disease, aqueous tear deficiency, and meibomian 85 
gland dysfunction were based on the global consensus recommendations of the Tear Film 86 
 
 
and Ocular Surface Society Dry Eye Workshop II and the International Workshop on 87 
Meibomian Gland Dysfunction,[7-9] as summarised in Table 2. 88 
 89 
Past medical history, including diagnosed medical conditions, ophthalmic surgery, oral 90 
medications, and topical ophthalmic medications were recorded. The systemic risk factors 91 
investigated in the current study were based on those identified in the TFOS DEWS II 92 
Epidemiology Report and recent dry eye epidemiology studies,[1, 10-12] and included acne 93 
vulgaris, allergic rhinitis, anxiety, asthma, diabetes, depression, dyslipidaemia, eczema, 94 
hypertension, malignancy, migraine headaches, menopause, ovarian dysfunction, systemic 95 
rheumatologic disease, thyroid disease, cataract surgery, refractive surgery, other 96 
ophthalmic surgery, antidepressant medication, antihistamine medication, antihypertensive 97 
medication, hormone replacement therapy, oral contraceptive therapy, sedative medication, 98 
topical anti-glaucoma medication, topical antihistamine medication. Participants with 99 
rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, psoratic arthritis, and 100 
ankylosing spondylitis, were included under the classification of systemic rheumatologic 101 
disease. None of the participants reported a history of Sjögren syndrome, chronic kidney 102 
disease, or hematopoietic stem cell transplantation. 103 
 104 
The Ocular Surface Disease Index (OSDI) and 5-Item Dry Eye Questionnaire (DEQ-5) were 105 
administered to grade the level of dry eye symptomology, as recommended by the TFOS 106 
DEWS II Diagnostic Methodology subcommittee.[7] 107 
 108 
Tear meniscus height, non-invasive tear film breakup time, and tear film lipid layer grade 109 
were assessed using the Keratograph 5M (Oculus Optikgeräte GmbH, Wetzlar, Germany). 110 
The lower tear meniscus height was evaluated using high magnification pre-calibrated digital 111 
imaging, and three measurements near the centre of the lower meniscus were averaged. 112 
Non-invasive tear film breakup time was determined by automated detection of first break-113 
up, while the subject maintained fixation and was requested to refrain from blinking. Three 114 
 
 
breakup time readings were averaged in each case.[7] Tear film lipid layer interferometry 115 
was graded according to the modified Guillon-Keeler system: grade 1, open meshwork; 116 
grade 2, closed meshwork; grade 3, wave or flow; grade 4, amorphous; grade 5, coloured 117 
fringes; grade 0, non-continuous layer (non-visible or abnormal coloured fringes).[13, 14] 118 
 119 
Tear film osmolarity measurements were conducted with a clinical osmometer (TearLab, 120 
California, USA), from 50nL tear samples collected from the lower lateral canthus tear 121 
meniscus. A measurement was taken for each eye, and the higher reading and the inter-122 
ocular difference recorded.[7] 123 
 124 
Sodium fluorescein and lissamine green dyes were applied using the recommended 125 
technique described in the TFOS DEWS II Diagnostic Methodology report, in order to 126 
evaluate localised corneal and conjunctival areas of epithelial desiccation, and lid wiper 127 
epitheliopathy.[7] Corneal and conjunctival staining was assessed using the Sjögren's 128 
Syndrome International Registry classification scheme,[15] and upper and lower lid wiper 129 
epitheliopathy was evaluated relative to Korb’s grading scheme.[16] 130 
 131 
Infrared meibography was imaged with the Oculus Keratograph 5M, with the superior and 132 
inferior eyelids everted in turn.[9] From the captured image, the proportion of meibomian 133 
glands visible within the tarsal area were graded according to the five-point Meiboscale.[17] 134 
 135 
2.3. Statistics 136 
 137 
Statistical analysis was conducted with Graph Pad Prism version 8.01 (California, USA) and 138 
IBM SPSS version 24 (New York, USA). Preliminary univariate logistic regression was used 139 
to identify potential predictors of dry eye disease, aqueous tear deficiency, and meibomian 140 
gland dysfunction. Multivariate logistic regression for predictors of dry eye disease, aqueous 141 
tear deficiency, and meibomian gland dysfunction was then conducted, incorporating 142 
 
 
variables with a univariate association threshold of p<0.15. The number of variables used in 143 
the multivariate regression analysis was limited to the number of diagnosed participants 144 
divided by 10, to avoid overfitting. All tests were two tailed, and p<0.05 was considered 145 
significant. Data are presented as mean±SD, median (IQR), or number of participants (% of 146 
participants) unless otherwise stated.  147 
 
 
3. RESULTS 148 
 149 
The mean ± SD age of the 372 community residents recruited (222 females, 150 males) was 150 
39±22 years (range, 21 to 85 years). Seventy-one (19%) participants were university 151 
students, 43 (12%) were university staff members, and 258 (69%) were members of the 152 
general public. Demographic, systemic, and ophthalmic characteristics of participants are 153 
presented in Tables 3 to 5. Overall, 109 (29%) participants fulfilled the TFOS DEWS II 154 
criteria for dry eye disease, 42 (11%) had aqueous tear deficiency, and 95 (26%) had 155 
meibomian gland dysfunction. Correlation analysis and the contributions of individual 156 
diagnostic tests to disease prevalence are presented in Supplementary Tables 1 and 2. 157 
 158 
Unadjusted univariate and multivariate-adjusted odds ratios of dry eye disease, aqueous 159 
tear deficiency, and meibomian gland dysfunction by demographic and clinical 160 
characteristics are presented in Tables 6 to 8. Multivariate logistic regression demonstrated 161 
that systemic rheumatologic disease and antidepressant medication were independently 162 
associated with aqueous tear deficiency (both p<0.05). Significant risk factors for meibomian 163 
gland dysfunction included advancing age, East Asian ethnicity, migraine headaches, thyroid 164 
disease, and oral contraceptive therapy (all p≤0.01). 165 
 166 
Sensitivity analysis conducted by incorporating depression and all confounding predictors of 167 
aqueous tear deficiency with univariate p<0.15 in the multivariate logistic regression model, 168 
but excluding antidepressant medication, demonstrated no significant association between 169 
depression and aqueous tear deficiency (p=0.31).  170 
 
 
4. DISCUSSION 171 
 172 
To our knowledge, this study is among the first to assess systemic risk factors of dry eye 173 
disease using the global consensus TFOS DEWS II diagnostic criteria.[7] The results 174 
showed that dry eye disease was associated with a number of risk factors including 175 
advancing age, East Asian ethnicity, systemic rheumatologic disease, migraine headaches, 176 
thyroid disease, antidepressant medication, and oral contraceptive therapy. Although the risk 177 
factors identified for aqueous tear deficiency were largely consistent with earlier studies, a 178 
number of the systemic associations identified for meibomian gland dysfunction had been 179 
previously classified by the TFOS DEWS II Epidemiology report as probable or 180 
inconclusive.[1]  181 
 182 
In agreement with earlier reports,[1, 18-21] the findings of the current study demonstrated 183 
that ageing was positively associated with dry eye disease and meibomian gland 184 
dysfunction. Dry eye disease and meibomian gland dysfunction are thought to be 185 
degenerative conditions that progress with cumulative lifetime exposure to a myriad of 186 
environmental and physiological factors, which contribute to hormonal changes, 187 
neurosensory abnormalities, ocular surface inflammation, and tear film homeostatic 188 
disturbances.[1, 5, 6]  189 
 190 
East Asian ethnicity was identified to be an independent risk factor for dry eye disease and 191 
meibomian gland dysfunction in the current study, which was comparable with the trends 192 
observed in earlier reports across different age groups.[1, 22-25] It has been previously 193 
hypothesised that the East Asian ethnic propensity towards the development of dry eye 194 
disease might be related to anatomical differences that lead to increased eyelid tension, 195 
including higher axial length, the more inferior aponeurotic attachment point of levator 196 
palpebrae superioris, and differences in orbital connective tissue distribution.[19] These 197 
 
 
factors may contribute to the increased tendency to incomplete blinking, and subsequently 198 
accelerated rates of meibomian gland dropout.[24, 26] 199 
 200 
Systemic factors associated with meibomian gland dysfunction observed in the current study 201 
included migraine headaches, thyroid disease, and oral contraceptive therapy. Although the 202 
mechanisms are not yet fully understood, the association between migraine headaches and 203 
dry eye disease may be potentially related to underlying inflammatory processes, which play 204 
a significant role in the pathophysiology of both conditions, as highlighted by earlier studies 205 
which report similar trends.[11, 27-29] Neurovascular inflammatory mediators and cytokines 206 
have been implicated in plasma extravasation and trigeminal ganglion hypersensitivity in the 207 
development of migraines.[11, 28, 29] It remains yet to be established whether the 208 
regulatory action of sex steroids, hypothalamic-pituitary and thyroid hormones on the 209 
immune system and ocular surface might also contribute.[30] Moreover, it has been 210 
hypothesised that hyper-stimulation of the trigeminal ganglion with ocular irritation and reflex 211 
tearing associated with dry eye disease might further exacerbate the progression of migraine 212 
headaches.[11, 29] The relationship between thyroid disorders and evaporative dry eye 213 
disease has also been identified in previous studies,[31-33] and might be partially mediated 214 
by the predisposition to incomplete lid closure incomplete blinking with inflammation and 215 
swelling of orbital tissues associated with both hyperthyroidism and hypothyroidism, as well 216 
as exophthalmos in Graves’ orbitopathy.[1, 26, 33] There have been inconsistent reports of 217 
the effects of oral contraceptive therapy on dry eye disease in earlier studies,[1, 34, 35] and 218 
it is thought that the association might be related to the role of oestrogen in the 219 
downregulation of lipid synthesis in the meibomian glands, as well as the compounding 220 
effects of oestrogen and progesterone in modulating inflammatory pathways.[1, 30]  221 
 222 
Independent risk factors for aqueous tear deficiency identified in the current study included 223 
systemic rheumatologic disease and antidepressant medication. The association between 224 
systemic rheumatologic conditions and aqueous deficient dry eye disease has been well 225 
 
 
established in earlier studies,[1, 36, 37] and is likely related to inflammatory infiltration and 226 
structural damage of the lacrimal glands resulting in compromised secretory function.[1, 5] 227 
The suppressant action of antidepressant medication on lacrimal function has been 228 
previously reported, and is thought to be mediated by the effects of serotonin on the 229 
sensitivity thresholds of corneal nerves and the neuronal regulation of lacrimal secretion.[38-230 
40] 231 
 232 
Overall, both etiological subtypes of dry eye disease were associated with a number of 233 
systemic risk factors. These findings would support routine systemic inquiry of dry eye 234 
symptoms in patients affected by associated conditions and medications, in order to facilitate 235 
opportunistic screening and timely referral to eye care practitioners where necessary. The 236 
results also highlight the importance of eye care practitioners taking a careful history 237 
exploring relevant systemic conditions and medications when evaluating patients with dry 238 
eye disease, which might facilitate the identification of potentially modifiable risk factors. [1, 239 
18, 41, 42]  240 
 241 
This study is not without limitations. Past medical history was self-reported by participants, 242 
which can introduce recall bias. The convenience sample based in a single university centre 243 
might introduce selection bias, and the open advertisement recruitment process may 244 
potentially be associated with volunteer bias, which might lead to a higher than expected 245 
prevalence of dry eye disease among the study cohort. However, it is noted that the current 246 
study cohort was comprised of generally healthy community residents, rather than a 247 
hospital-based convenience sample of clinic patients. Seasonal variation during the 248 
participant recruitment period, from January 2018 to June 2019, is acknowledged to 249 
potentially contribute to variability in clinical signs and symptoms of dry eye disease, 250 
although participants were assessed in a single site, within a temperature and humidity-251 
controlled environment. It is possible that the measurement of right eye ocular surface 252 
parameters might potentially result in underestimation of the prevalence rate of dry eye 253 
 
 
disease, although this effect would not be expected to be marked in the context of dry eye 254 
disease typically being bilateral and relatively symmetrical.[7] The wide confidence intervals 255 
of a number of effect estimates reflect the lower prevalence of the risk factors investigated, 256 
and associated limitations of decreased study power. In total, 32 risk factors were tested in 257 
three possible outcome variables, which could have led to false positive results, as 258 
significance levels were not adjusted for multiple testing. Future studies with larger sample 259 
sizes would be required to confirm the hypotheses generated in this exploratory study, but 260 
also to further analyse risk factors that did not reach statistical significance in the current 261 
study. 262 
 263 
5. Conclusions 264 
 265 
In conclusion, both etiological subtypes of dry eye disease were associated with a number of 266 
systemic risk factors. Migraine headaches, thyroid disease, and oral contraceptive therapy 267 
were independently associated with meibomian gland dysfunction, while systemic 268 
rheumatologic disease and antidepressant medication were significant risk factors for 269 
aqueous tear deficiency. The findings of this study would support routine systemic inquiry in 270 
order to facilitate opportunistic screening and timely inter-disciplinary referral for the 271 
optimisation of modifiable systemic factors, such as disease activity and medication use, 272 
where necessary. 273 
 274 
 275 
  276 
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1. Past medical history 
2. OSDI dry eye questionnaire 
3. DEQ-5 dry eye questionnaire 
4. Tear meniscus height 
5. Non-invasive tear film breakup time 
6. Tear film lipid layer grade 
7. Tear osmolarity 
8. Ocular surface staining 
9. Infrared meibography 
 399 
  400 
 
 
Table 2: Diagnostic criteria for dry eye disease, aqueous tear deficiency, and meibomian 401 
gland dysfunction based on the global consensus recommendations of the Tear Film and 402 
Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) and the International 403 





Dry eye disease 
 




• Non-invasive tear film breakup time <10s, tear 
osmolarity ≥308mOsm/L, inter-ocular difference 
in osmolarity >8mOsm/L, corneal staining >5 
spots, conjunctival staining >9 spots, or lid 
margin staining ≥2mm length and ≥25% width 
 
 
Aqueous tear deficiency 
 




• Tear meniscus height <0.2mm 
 
 
Meibomian gland dysfunction 
 








  408 
 
 
Table 3: Demographic and clinical characteristics of participants. Data is presented as mean 409 




Age (years) 39±22 
Female sex 222 (60%) 
Contact lens wear 107 (29%) 
European ethnicity 155 (42%) 
East Asian ethnicity 142 (38%) 
South Asian ethnicity 38 (10%) 
Other ethnicity 37 (10%) 
Medical history  
Acne vulgaris 16 (4%) 
Allergic rhinitis 37 (10%) 
Anxiety 25 (7%) 
Asthma 16 (4%) 
Diabetes 23 (6%) 
Depression 27 (7%) 
Dyslipidaemia 29 (8%) 
Eczema 20 (5%) 
Hypertension 49 (13%) 
Malignancy 8 (2%) 
Migraine headaches 33 (9%) 
Menopause 73 (20%) 
Ovarian dysfunction 16 (4%) 
Systemic rheumatologic disease 11 (3%) 
Thyroid disease 18 (5%) 
Ophthalmic surgery  
Cataract surgery 13 (3%) 
Refractive surgery 15 (4%) 
Other ophthalmic surgery 19 (5%) 
Oral medications  
Antidepressant medication 23 (6%) 
Antihistamine medication 32 (9%) 
Antihypertensive medication 38 (10%) 
Hormone replacement therapy 9 (2%) 
Oral contraceptive therapy 42 (11%) 
Sedative medication 31 (8%) 
Topical ocular medications  
Topical anti-glaucoma medication 12 (3%) 
Topical antihistamine medication 15 (4%) 
 412 
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Table 4: Ocular surface characteristics of participants. Data is presented as mean ± SD, 414 
median (IQR), or number of participants (% of participants). 415 
 416 
Characteristic Values 
Dry eye symptomology  
OSDI score 12 (6-31) 
DEQ-5 score 5 (3-10) 
Tear film quality  
Non-invasive tear film breakup time (s) 8.9 (4.8-13.6) 
Tear film osmolarity (mOsmol/L) 306±12 
Inter-ocular difference in osmolarity (mOsmol/L) 6 (3-12) 
Tear film lipid layer grade 3 (2-4) 
Tear meniscus height (mm) 0.27±0.12 
Ocular surface characteristics  
Corneal staining >5 spots 34 (9%) 
Conjunctival staining >9 spots 71 (19%) 
Lid margin staining ≥2mm length and ≥25% width 97 (26%) 
Superior meibography grade 1 (0-2) 
Inferior meibography grade 1 (0-2) 
Dry eye disease diagnostic criteria  
Overall diagnosis of dry eye disease 109 (29%) 
Aqueous tear deficiency 42 (11%) 
Meibomian gland dysfunction 95 (26%) 
 417 
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Table 5: Frequency of dry eye disease, aqueous tear deficiency, and meibomian gland 419 
dysfunction by participant age and sex. Data is presented as number of participants (% of 420 
participants). 421 
 422 







16 to 39 Female 23/109 (21%) 8/109 (7%) 19/109 (17%) 
Male 13/86 (15%) 3/86 (3%) 12/86 (14%) 
40 to 59 Female 21/58 (36%) 10/58 (17%) 18/58 (31%) 
Male 11/33 (33%) 4/33 (12%) 10/33 (30%) 
≥60 Female 27/55 (49%) 11/55 (20%) 24/55 (44%) 
Male 14/31 (45%) 6/31 (19%) 12/31 (39%) 
 423 
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Table 6: Logistic regression odds ratio of dry eye disease by demographic and clinical 425 







OR (95% CI) p OR (95% CI) p 
Demographics     
Age (per 10 years) 1.15 (1.04-1.27) 0.008* 1.19 (1.05-1.36) 0.007* 
Female sex 1.39 (0.87-2.20) 0.17 - - 
Contact lens wear 1.69 (1.05-2.74) 0.03* 1.31 (0.76-2.24) 0.33 
East Asian versus European ethnicity 1.82 (1.09-3.04) 0.02* 2.48 (1.35-4.58) 0.004* 
South Asian versus European ethnicity 1.05 (0.46-2.41) 0.92 - - 
Other versus European ethnicity 1.18 (0.49-2.79) 0.85 - - 
Medical history     
Acne vulgaris 1.94 (0.70-5.34) 0.21 - - 
Allergic rhinitis 1.35 (0.66-2.76) 0.41 - - 
Anxiety 1.67 (0.61-3.78) 0.23 - - 
Asthma 1.47 (0.52-4.16) 0.45 - - 
Diabetes 0.81 (0.16-4.03) 0.79 - - 
Depression 1.73 (0.78-3.87) 0.18 - - 
Dyslipidaemia 0.75 (0.31-1.82) 0.53 - - 
Eczema 1.32 (0.51-3.40) 0.57 - - 
Hypertension 0.69 (0.23-2.11) 0.51 - - 
Malignancy 0.81 (0.16-4.03) 0.79 - - 
Migraine headaches 2.49 (1.21-5.13) 0.01* 2.96 (1.38-6.37) 0.005* 
Menopause 1.81 (1.05-3.08) 0.03* 1.33 (0.59-2.97) 0.49 
Ovarian dysfunction 0.80 (0.25-2.52) 0.71 - - 
Systemic rheumatologic disease 4.43 (1.27-15.51) 0.02* 4.39 (1.13-16.23) 0.03* 
Thyroid disease 5.29 (1.94-14.51) 0.001* 5.15 (1.69-15.74) 0.004* 
Ophthalmic surgery     
Cataract surgery 1.08 (0.32-3.57) 0.91 - - 
Refractive surgery 1.22 (0.41-3.65) 0.73 - - 
Other ophthalmic surgery 1.44 (0.55-3.75) 0.46 - - 
Oral medications     
Antidepressant medication 2.83 (1.21-6.64) 0.02* 3.05 (1.18-7.87) 0.02* 
Antihistamine medication 0.95 (0.42-2.10) 0.88 - - 
Antihypertensive medication 0.73 (0.33-1.59) 0.42 - - 
Hormone replacement therapy 1.97 (0.52-7/46) 0.32 - - 
Oral contraceptive therapy 2.20 (1.15-4.24) 0.02* 2.58 (1.23-5.42) 0.01* 
Sedative medication 0.94 (0.42-2.10) 0.88 - - 
Topical ophthalmic medications     
Topical anti-glaucoma medication 1.76 (0.55-5.67) 0.33 - - 
Topical antihistamine medication 1.64 (0.57-4.74) 0.36 - - 
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Table 7: Logistic regression odds ratio of aqueous tear deficiency by demographic and 430 







OR (95% CI) p OR (95% CI) p 
Demographics     
Age (per 10 years) 1.13 (0.98-1.31) 0.09 1.08 (0.93-1.26) 0.32 
Female sex 1.58 (0.79-3.16) 0.19 - - 
Contact lens wear     
East Asian versus European ethnicity 1.18 (0.59-2.34) 0.51 - - 
South Asian versus European ethnicity 1.53 (0.43-5.49) 0.65 - - 
Other versus European ethnicity 0.44 (0.11-1.96) 0.28 - - 
Medical history     
Acne vulgaris 1.13 (0.25-5.14) 0.88 - - 
Allergic rhinitis 0.95 (0.32-2.82) 0.92 - - 
Anxiety 1.55 (0.51-4.75) 0.44 - - 
Asthma 1.88 (0.51-6.87) 0.34 - - 
Diabetes 1.13 (0.14-9.38) 0.91 - - 
Depression 1.89 (0.68-5.29) 0.23 - - 
Dyslipidaemia 0.90 (0.26-3.11) 0.87 - - 
Eczema 2.07 (0.77-6.49) 0.21 - - 
Hypertension 0.98 (0.22-4.43) 0.98 - - 
Malignancy 2.70 (0.53-13.83) 0.23 - - 
Migraine headaches 1.87 (0.72-4.84) 0.19 - - 
Menopause 2.30 (1.14-4.63) 0.02* 2.63 (0.89-7.81) 0.08 
Ovarian dysfunction 1.13 (0.25-5.15) 0.88 - - 
Systemic rheumatologic disease 7.30 (2.12-25.08) 0.002* 6.51 (1.85-22.99) 0.004* 
Thyroid disease 0.98 (0.22-4.43) 0.98 - - 
Ophthalmic surgery     
Cataract surgery 0.65 (0.08-5.10) 0.68 - - 
Refractive surgery 1.22 (0.27-5.60) 0.80 - - 
Other ophthalmic surgery 1.51 (0.42-5.42) 0.53 - - 
Oral medications     
Antidepressant medication 3.93 (1.51-10.19) 0.005* 3.23 (1.19-8.79) 0.02* 
Antihistamine medication 0.80 (0.23-2.74) 0.72 - - 
Antihypertensive medication 0.65 (0.19-2.21) 0.49 - - 
Hormone replacement therapy 0.98 (0.12-8.05) 0.99 - - 
Oral contraceptive therapy 1.69 (0.70-4.08) 0.25 - - 
Sedative medication 1.58 (0.57-4.35) 0.38 - - 
Topical ophthalmic medications     
Topical anti-glaucoma medication 2.74 (0.71-10.57) 0.14 - - 
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Table 8: Logistic regression odds ratio of meibomian gland dysfunction by demographic and 437 







OR (95% CI) p OR (95% CI) p 
Demographics     
Age (per 10 years) 1.17 (1.05-1.30) 0.004* 1.24 (1.05-1.48) 0.01* 
Female sex 1.29 (0.80-2.10) 0.30 - - 
Contact lens wear 1.66 (1.01-2.73) 0.045* 1.31 (0.74-2.27) 0.36 
East Asian versus European ethnicity 2.04 (1.21-3.45) 0.008* 2.79 (1.47-5.30) 0.002* 
South Asian versus European ethnicity 1.24 (0.53-2.89) 0.62 - - 
Other versus European ethnicity 1.07 (0.43-2.67) 0.88 - - 
Medical history     
Acne vulgaris     
Allergic rhinitis 1.26 (0.60-2.67) 0.54 - - 
Anxiety 1.41 (0.59-3.37) 0.45 - - 
Asthma 1.80 (0.64-5.09) 0.27 - - 
Diabetes 0.97 (0.19-4.89) 0.97 - - 
Depression 1.51 (0.65-3.48) 0.34 - - 
Dyslipidaemia 0.59 (0.22-1.58) 0.29 - - 
Eczema 0.97 (0.34-2.750 0.96 - - 
Hypertension 0.57 (0.16-2.01) 0.38 - - 
Malignancy 0.97 (0.19-4.89) 0.97 - - 
Migraine headaches 3.56 (1.72-7.36) 0.001* 3.90 (1.76-8.66) 0.001* 
Menopause 1.84 (1.07-3.19) 0.03* 1.19 (0.55-2.59) 0.66 
Ovarian dysfunction 0.97 (0.31-3.09) 0.96 - - 
Systemic rheumatologic disease 1.69 (0.49-5.93) 0.41 - - 
Thyroid disease 6.53 (2.38-17.94) <0.001* 5.84 (2.03-16.83) 0.001* 
Ophthalmic surgery     
Cataract surgery 1.31 (0.39-4.35) 0.66 - - 
Refractive surgery 1.48 (0.49-4.46) 0.48 - - 
Other ophthalmic surgery 1.76 (0.67-4.60) 0.25 - - 
Oral medications     
Antidepressant medication 1.97 (0.82-4.70) 0.13 - - 
Antihistamine medication 0.97 (0.42-2.24) 0.94 - - 
Antihypertensive medication 0.76 (0.33-1.71) 0.51 - - 
Hormone replacement therapy 2.39 (0.63-9.09) 0.20 - - 
Oral contraceptive therapy 2.20 (1.13-4.28) 0.02* 2.58 (1.21-5.52) 0.01* 
Sedative medication 1.43 (0.65-3.15) 0.38 - - 
Topical ophthalmic medications     
Topical anti-glaucoma medication 2.14 (0.66-6.91) 0.20 - - 
Topical antihistamine medication 2.01 (0.71-5.79) 0.18 - - 
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